The therapeutic value of our strategy is demonstrated by programmed silencing of critical targets associated with various diseases, including EGFR/KRAS in lung cancer, EGFR/TNC in glioblastoma and PTP1B in obesity. This evidence concerns the gene KRAS and obesity due to melanocortin 4 receptor deficiency.